Literature DB >> 17765523

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.

A Sonia Buist1, Mary Ann McBurnie, William M Vollmer, Suzanne Gillespie, Peter Burney, David M Mannino, Ana M B Menezes, Sean D Sullivan, Todd A Lee, Kevin B Weiss, Robert L Jensen, Guy B Marks, Amund Gulsvik, Ewa Nizankowska-Mogilnicka.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide, and accurate estimates of the prevalence of this disease are needed to anticipate the future burden of COPD, target key risk factors, and plan for providing COPD-related health services. We aimed to measure the prevalence of COPD and its risk factors and investigate variation across countries by age, sex, and smoking status.
METHODS: Participants from 12 sites (n=9425) completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors. COPD prevalence estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted for the target population. Logistic regression was used to estimate adjusted odds ratios (ORs) for COPD associated with 10-year age increments and 10-pack-year (defined as the number of cigarettes smoked per day divided by 20 and multiplied by the number of years that the participant smoked) increments. Meta-analyses provided pooled estimates for these risk factors.
FINDINGS: The prevalence of stage II or higher COPD was 10.1% (SE 4.8) overall, 11.8% (7.9) for men, and 8.5% (5.8) for women. The ORs for 10-year age increments were much the same across sites and for women and men. The overall pooled estimate was 1.94 (95% CI 1.80-2.10) per 10-year increment. Site-specific pack-year ORs varied significantly in women (pooled OR=1.28, 95% CI 1.15-1.42, p=0.012), but not in men (1.16, 1.12-1.21, p=0.743).
INTERPRETATION: This worldwide study showed higher levels and more advanced staging of spirometrically confirmed COPD than have typically been reported. However, although age and smoking are strong contributors to COPD, they do not fully explain variations in disease prevalence-other factors also seem to be important. Although smoking cessation is becoming an increasingly urgent objective for an ageing worldwide population, a better understanding of other factors that contribute to COPD is crucial to assist local public-health officials in developing the best possible primary and secondary prevention policies for their regions.

Entities:  

Mesh:

Year:  2007        PMID: 17765523     DOI: 10.1016/S0140-6736(07)61377-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  657 in total

1.  Cognitive and Perceptual Factors, Not Disease Severity, Are Linked with Anxiety in COPD: Results from a Cross-Sectional Study.

Authors:  Elyse R Thakur; Shubhada Sansgiry; Nancy J Petersen; Melinda Stanley; Mark E Kunik; Aanand D Naik; Jeffrey A Cully
Journal:  Int J Behav Med       Date:  2018-02

Review 2.  Effect of respiratory rehabilitation techniques on the autonomic function in patients with chronic obstructive pulmonary disease: A systematic review.

Authors:  Jibril Mohammed; Hellen Da Silva; Jessica Van Oosterwijck; Patrick Calders
Journal:  Chron Respir Dis       Date:  2016-12-15       Impact factor: 2.444

3.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

Review 4.  Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.

Authors:  Daniel J Hassett; Michael T Borchers; Ralph J Panos
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

5.  Functional polymorphisms in NFκB1/IκBα predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese.

Authors:  Dongsheng Huang; Lei Yang; Yehua Liu; Yumin Zhou; Yuan Guo; Mingan Pan; Yunnan Wang; Yigang Tan; Haibo Zhong; Min Hu; Wenju Lu; Weidong Ji; Jian Wang; Pixin Ran; Nanshan Zhong; Yifeng Zhou; Jiachun Lu
Journal:  Hum Genet       Date:  2013-01-16       Impact factor: 4.132

Review 6.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

7.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

8.  Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.

Authors:  Yosuke Yamada; Utano Tomaru; Akihiro Ishizu; Tomoki Ito; Takayuki Kiuchi; Ayako Ono; Syota Miyajima; Katsura Nagai; Tsunehito Higashi; Yoshihiro Matsuno; Hirotoshi Dosaka-Akita; Masaharu Nishimura; Soichi Miwa; Masanori Kasahara
Journal:  Lab Invest       Date:  2015-04-27       Impact factor: 5.662

9.  Effects of Integrated Case Payment on Medical Expenditure and Readmission of Inpatients with Chronic Obstructive Pulmonary Disease: A Nonrandomized, Comparative Study in Xi County, China.

Authors:  Meng Shi; Jing Wang; Liang Zhang; Yan Yan; Yu-Dong Miao; Xiang Zhang
Journal:  Curr Med Sci       Date:  2018-06-22

Review 10.  Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.

Authors:  Vanessa M McDonald; Isabel Higgins; Peter G Gibson
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.